Elopag (Eltrombopag) 25 mg , 50 mg

Category:

DESCRIPTION

Elopag is a prescription drug used for the treatment of Thrombocytopenia in patients with Chronic ITP, Thrombocytopenia in patients with Hepatitis C infection and Severe Aplastic Anemia. To buy Elopag or to know its price contact 3S Corporation.

Manufacturer :  Everest Pharmaceuticals Ltd

ADDITIONAL INFORMATION

Strengths available25 mg , 50 mg

Form : Tablets

Dosage : Recommended dosage for Thrombocytopenia in patients with Chronic ITP– (Initial Dose Regimen) :  (Adult and Pediatric Patients 6 Years and Older with ITP) Initiate Elopag at a dose of 50 mg once daily, except in patients who are of Asian ancestry (such as Chinese, Japanese, Taiwanese, or Korean) or who have mild to severe hepatic impairment (Child-Pugh Class A, B, C).For patients of Asian ancestry with ITP, initiate Elopag at a reduced dose of 25 mg once daily.

For patients with ITP and mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, C), initiate Elopag at a reduced dose of 25 mg once daily. For patients of Asian ancestry with ITP and hepatic impairment (Child-Pugh Class A, B, C), consider initiating Elopag at a reduced dose of 12.5 mg once daily.

Pediatric Patients with ITP Aged 1 to 5 Years– Initiate Elopag at a dose of 25 mg once daily.

Recommended dosage for Thrombocytopenia in patients with Hepatitis C infection –(Initial Dose Regimen)- Initiate Elopag at a dose of 25 mg once daily.

Recommended dosage for Severe Aplastic Anemia- (Initial Dose Regimen)– Initiate Elopag at a dose of 50 mg once daily.

SIDE EFFECTS

Common side effects are insomnia, dizziness, headache, cough, dyspnea, nausea, oropharyngeal pain, rhinorrhea, abdominal pain, diarrhea, ecchymosis, transaminases increased, arthralgia, muscle spasms, pain in extremity, febrile neutropenia, pyrexia and fatigue.

PACK SIZE

Bottle of 14 tablets

Reviews

There are no reviews yet.

Be the first to review “Elopag (Eltrombopag) 25 mg , 50 mg”

Your email address will not be published. Required fields are marked *